B. Chackerian

发表

High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse).

D. Lowy, M. Sherman, S. Kjaer, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The Targeted Delivery of Multicomponent Cargos to Cancer Cells via Nanoporous Particle-Supported Lipid Bilayers

Mark B. Carter, Cheryl L. Willman, C. Jeffrey Brinker, 2011, Nature materials.

Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.

Mark B. Carter, Genevieve K Phillips, C Jeffrey Brinker, 2011, ACS nano.

Cell-Speci fi cDelivery of Diverse Cargos byBacteriophageMS 2 Virus-likeParticles

Mark B. Carter, Eric C. Carnes, C. Brinker, 2011 .

Erratum: The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers (Nature Materials (2011) 10 (389-397))

Mark B. Carter, Cheryl L. Willman, C. Jeffrey Brinker, 2011 .

Author ' s personal copy

D. Peabody, B. Chackerian, Julianne Peabody, 2007 .

Persistence of simian immunodeficiency virus Mne variants upon transmission

J. Overbaugh, B. Chackerian, W. Morton, 1994, Journal of virology.

Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

S. Kazer, A. Shalek, P. McTamney, 2019, Immunity.

Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.

D. Peabody, B. Chackerian, Pavan Muttil, 2016, Molecular pharmaceutics.

Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.

D. Peabody, B. Chackerian, Pavan Muttil, 2015, Vaccine.

A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice.

A. Remaley, B. Chackerian, M. Sampson, 2021, Vaccine.

Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

J. Schiller, D. Peabody, B. Chackerian, 2010, Vaccine.

VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus

D. Peabody, B. Chackerian, Julianne Peabody, 2012, PloS one.

Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9

Dominique N. Price, N. Kunda, B. Chackerian, 2019, Human vaccines & immunotherapeutics.

A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.

D. Peabody, B. Chackerian, Julianne Peabody, 2013, Vaccine.

Vaccination with VLPs Presenting a Linear Neutralizing Domain of S. aureus Hla Elicits Protective Immunity

D. Peabody, P. Hall, Seth M. Daly, 2020, Toxins.

Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

H. Smyth, B. Chackerian, Paul N Durfee, 2009, Vaccine.

Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development

J. Schiller, B. Chackerian, 2014, PLoS pathogens.

VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation

D. Peabody, K. Frietze, P. Hall, 2017, Scientific Reports.

Delivery of Ricin Toxin A‐Chain by Peptide‐Targeted Mesoporous Silica Nanoparticle‐Supported Lipid Bilayers

Jason L. Townson, Dan C. Wilkinson, Eric C. Carnes, 2012, Advanced healthcare materials.

Assessing Antibody Specificity in Human Serum Using Deep Sequence-Coupled Biopanning.

D. Peabody, K. Frietze, B. Chackerian, 2020, Methods in molecular biology.

Pathogen-specific deep sequence-coupled biopanning: A method for surveying human antibody responses

J. Pascale, D. Peabody, K. Frietze, 2017, PloS one.

Particles Conjugated Papillomavirus Virus-Like Determinants of Autoantibody Induction by Schiller

P. Lenz, D. Lowy, B. Chackerian, 2002 .

An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein

N. Petrovsky, B. Chackerian, F. Zavala, 2021, npj Vaccines.

Factors That Govern the Induction of Long-Lived Antibody Responses

D. Peabody, B. Chackerian, 2020, Viruses.

Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model1

J. Schiller, B. Chackerian, Marisa R. Durfee, 2008, The Journal of Immunology.

Transgenic Mouse Model Reverses B Cell Anergy in a B Cell Receptor Virus-Like Display of a Neo-Self Antigen

J. Schiller, B. Chackerian, Marisa R. Durfee, 2008 .

A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice

A. Remaley, B. Chackerian, M. Sampson, 2021, bioRxiv.

A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model

N. Petrovsky, B. Chackerian, Y. Flores-Garcia, 2021, bioRxiv.

Changes in the Extracellular Envelope Glycoprotein of Variants That Evolve during the Course of Simian Immunodeficiency Virus SIVMne Infection Affect Neutralizing Antibody Recognition, Syncytium Formation, and Macrophage Tropism but Not Replication, Cytopathicity, or CCR-5 Coreceptor Recognition

J. Overbaugh, B. Chackerian, J. Kimata, 1998, Journal of Virology.

Expansion and Refinement of Deep Sequence-Coupled Biopanning Technology for Epitope-Specific Antibody Responses in Human Serum

J. Pascale, D. Peabody, K. Frietze, 2020, Viruses.

Virus-like particle based vaccines for Alzheimer disease.

B. Chackerian, 2010, Human vaccines.

Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus

Paul S. Albert, D. Lowy, P. Albert, 2004, Journal of Virology.

RNA Phage VLP-Based Vaccine Platforms

Steven B. Bradfute, D. Peabody, B. Chackerian, 2021, Pharmaceuticals.

Moving towards a new class of vaccines for non-infectious chronic diseases

K. Frietze, B. Chackerian, Kathryn M. Frietze, 2016, Expert review of vaccines.

A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil‐9

J. Schiller, B. Chackerian, Julianne Peabody, 2017, Antiviral research.

Antibodies to Variable Domain 4 Linear Epitopes of the Chlamydia trachomatis Major Outer Membrane Protein Are Not Associated with Chlamydia Resolution or Reinfection in Women

C. Wheeler, D. Peabody, K. Frietze, 2020, Msphere.

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.

D. Lowy, J. Schiller, B. Chackerian, 2001, The Journal of clinical investigation.

Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.

Jason L. Townson, Dan C. Wilkinson, Eric C. Carnes, 2012, ACS nano.

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

D. Lowy, J. Schiller, B. Chackerian, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Genital delivery of virus-like particle and pseudovirus-based vaccines

B. Chackerian, N. Çuburu, 2011, Expert review of vaccines.

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2

D. Peabody, B. Chackerian, Julianne Peabody, 2011, PloS one.

Virus-like particles: flexible platforms for vaccine development

B. Chackerian, Bryce Chackerian, 2007, Expert review of vaccines.

Engineering virus-like particles as vaccine platforms.

D. Peabody, K. Frietze, B. Chackerian, 2016, Current opinion in virology.

An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein

N. Petrovsky, B. Chackerian, F. Zavala, 2020, bioRxiv.

Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

D. Ho, J. Mascola, J. Yu, 2020, Vaccines.

Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis

K. Frietze, B. Chackerian, Rebeccah S. Lijek, 2018, Expert review of vaccines.

Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature

B. Chackerian, Pavan Muttil, Julianne Peabody, 2017, Papillomavirus research.

Progress and prospects for L2-based human papillomavirus vaccines

R. Roden, B. Chackerian, Richard B S Roden, 2016, Expert review of vaccines.

Progress and prospects for L 2-based human papillomavirus vaccines

B. Chackerian, C. Schellenbacher, Rosie T. Jiang, 2016 .

A cholesterol-lowering VLP vaccine that targets PCSK9.

A. Remaley, J. Schiller, B. Chackerian, 2015, Vaccine.

Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.

D. Peabody, B. Chackerian, J. O’Rourke, 2015, Current opinion in virology.

The use of hybrid virus‐like particles to enhance the immunogenicity of a broadly protective HPV vaccine

D. Peabody, B. Chackerian, Ebenezer Tumban, 2014, Biotechnology and bioengineering.

Development of a Mimotope Vaccine Targeting the Staphylococcus aureus Quorum Sensing Pathway

D. Peabody, P. Hall, Seth M. Daly, 2014, PloS one.

Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

M. Ozbun, D. Peabody, A. Dziduszko, 2014, Vaccine.

Second-generation prophylactic HPV vaccines: successes and challenges

B. Chackerian, Ebenezer Tumban, Mitchell Tyler, 2014, Expert review of vaccines.

A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine

B. Chackerian, A. Salanti, A. Sander, 2019, Scientific Reports.

Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle Platform

D. Peabody, B. Chackerian, J. Caldeira, 2015, PloS one.

Immunogenicity and Protective Capacity of a Virus-like Particle Vaccine against Chlamydia trachomatis Type 3 Secretion System Tip Protein, CT584

C. Wheeler, B. Chackerian, W. Geisler, 2022, Vaccines.

Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy

Colin M. Wilson, J. Brigman, D. Peabody, 2019, npj Vaccines.

Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.

D. Peabody, B. Chackerian, Brett C. Manifold-Wheeler, 2008, Journal of molecular biology.

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses.

D. Peabody, B. Chackerian, Zoe N Hunter, 2006, Vaccine.

Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles

Petra Lenz, Douglas R Lowy, P. Lenz, 2002, The Journal of Immunology.

Induction of Autoantibodies to CCR 5 in Macaques and Subsequent Effects upon Challenge with an R 5-Tropic Simian / Human Immunodeficiency Virus

D. Lowy, P. Albert, J. Schiller, 2004 .

Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection

P. Luciw, J. Overbaugh, B. Chackerian, 1997, Journal of virology.

Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates.

N. Haigwood, J. Overbaugh, B. Chackerian, 1995, Virology.

Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses

R. Sidman, C. Wheeler, W. Cavenee, 2017, EMBO molecular medicine.

Cell-specific delivery by bacteriophage Single-molecule trapping Biofunctional quantum dots

Mark B. Carter, Eric C. Carnes, C. Brinker, 2011 .

Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies

J. Overbaugh, B. Chackerian, L. Rudensey, 1997, Journal of virology.

Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a

D. Peabody, C. King, B. Chackerian, 2018, The Journal of infectious diseases.

Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy

Colin M. Wilson, J. Brigman, D. Peabody, 2019, npj Vaccines.

Self-Antigens Displayed on Liposomal Nanoparticles above a Threshold of Epitope Density Elicit Class-Switched Autoreactive Antibodies Independent of T Cell Help

I. Grigorova, J. Moon, W. Cheng, 2019, The Journal of Immunology.

A Vaccine against CCR5 Protects a Subset of Macaques upon Intravaginal Challenge with Simian Immunodeficiency Virus SIVmac251

D. Montefiori, B. Keele, K. Abel, 2013, Journal of Virology.

Mechanisms of neutralizing antibody response probed using synthetic virus-like structures

J. Zikherman, W. Cheng, B. Chackerian, 2023, bioRxiv.

Engineering an Antibody V Gene-Selective Vaccine

Larance Ronsard, D. Lingwood, D. Rohrer, 2021, Frontiers in Immunology.

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

J. Schiller, K. Ugen, C. Cao, 2004, BMC Neuroscience.

The Immunogenicity of a VLP-based Malaria Vaccine Targeting CSP in Pregnant and Neonatal Mice

D. Peabody, B. Chackerian, L. Jelinkova, 2023, Biomolecules.

A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model

N. Petrovsky, B. Chackerian, Y. Flores-Garcia, 2022, npj Vaccines.

A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein

D. Peabody, B. Chackerian, R. Ord, 2014, Malaria Journal.

Targeted immunomodulation using antigen-conjugated nanoparticles.

S. Miller, L. Shea, D. McCarthy, 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

Development of a Potential Vaccine for Asthma Using IgE and Virus Like Particles

B. Chackerian, F. Monreal, 2009 .

Virus‐Like Particles as Antigen Scaffolds

J. Schiller, B. Chackerian, 2012 .

Virus-like particle based vaccines for Alzheimer disease

B. Chackerian, 2010 .

Virus-like Peptide Vaccines Against Aß N-terminal or C-Terminal Domains Reduce Amyloid Deposition in APP Transgenic Mice without Addition of Adjuvant

K. Ugen, D. Morgan, M. Gordon, 2010, Journal of Neuroimmune Pharmacology.

Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.

A. Dziduszko, B. Chackerian, Zoe N Hunter, 2011, Vaccine.

A method for mapping the linear epitopes targeted by the natural antibody response to Zika virus infection using a VLP platform technology.

Steven B. Bradfute, J. Pascale, D. Peabody, 2023, Virology.

Virus-Like Particle Based-Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

D. Ho, J. Mascola, P. Kwong, 2020 .

Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence–Coupled Biopanning Platform

R. Roden, D. Peabody, B. Chackerian, 2015, Cancer Immunology Research.

Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display

D. Peabody, B. Chackerian, D. Narum, 2015, PloS one.

Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles.

D. Peabody, B. Chackerian, Bryce Chackerian, 2011, Journal of molecular biology.

A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates

A. Remaley, J. Schiller, Debbie Lovato, 2023, bioRxiv.

Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9

A. Remaley, B. Chackerian, 2016, Current opinion in lipidology.

Initiation of neutralizing antibody response probed using synthetic virus-like structures

J. Zikherman, W. Cheng, B. Chackerian, 2023, bioRxiv.

A VACCINE-BASED STRATEGY FOR REDUCING CARDIOVASCULAR DISEASE RISK FACTORS

A. Remaley, I. Lindquist, B. Chackerian, 2017 .

Bacteriophage Virus-Like Particles as a Platform for Vaccine Discovery

D. Peabody, B. Chackerian, 2015 .

High-Risk Human Papillomavirus Is Sexually Transmitted : Evidence from a Follow-Up Study of Virgins Starting Sexual Activity ( Intercourse ) 1

D. Lowy, M. Sherman, S. Kjaer, 2001 .

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

J. Schiller, K. Ugen, C. Cao, 2004, BMC Neuroscience.

Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.

D. Peabody, B. Chackerian, J. O’Rourke, 2015, Current opinion in virology.

Engineering virus-like particles as vaccine platforms.

D. Peabody, B. Chackerian, Kathryn M. Frietze, 2016, Current opinion in virology.

A cholesterol-lowering VLP vaccine that targets PCSK9.

A. Remaley, J. Schiller, B. Chackerian, 2015, Vaccine.

Second-generation prophylactic HPV vaccines: successes and challenges

B. Chackerian, Ebenezer Tumban, Mitchell Tyler, 2014, Expert review of vaccines.

A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.

D. Peabody, B. Chackerian, Julianne Peabody, 2013, Vaccine.

Sequence and complementation analysis of recF genes from Escherichia coli, Salmonella typhimurium, Pseudomonas putida and Bacillus subtilis: evidence for an essential phosphate binding loop.

B. Chackerian, A. Clark, Johnny Li, 1992, Nucleic acids research.

Minimal Determinants for Lifelong Antiviral Antibody Responses in Mice from a Single Exposure to Virus-like Immunogens at Low Doses

J. Zikherman, W. Cheng, B. Chackerian, 2023, bioRxiv.

Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy

B. Chackerian, Nicole M. Maphis, Julianne Peabody, 2024, bioRxiv.